Literature DB >> 4680808

Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium.

R V McCloskey, E E Terry, A W McCracken, M J Sweeney, M F Forland.   

Abstract

Six patients undergoing chronic hemodialysis and 10 patients with chronic renal insufficiency hospitalized for nondialytic therapy received 1.0 g of cephapirin sodium by the intravenous route. The concentrations of cephapirin in arterial and venous plasma, dialysate, venous blood, and urine were measured during the ensuing 6 hr. The serum half-life of cephapirin was 105 to 108 min for the dialyzed patients and 95.9 min for the nondialyzed patients. Dialysis removed 22.8% of the administered dose. Nondialyzed patients excreted 19.5% of the administered dose in the urine. The concentration of cephapirin in the urine of all nondialyzed patients exceeded 50 mug/ml. The recovery of cephapirin in the urine collected for 6 hr after injection was from 34 to 770 mg (mean 195 mg). To maintain a concentration of cephapirin in the blood and urine which exceeds the minimal inhibitory concentration for most gram-positive and gram-negative microorganisms, nondialyzed patients should receive 15 to 18 mg of cephapirin per kg every 12 hr. Dialyzed patients should receive the same dose just prior to dialysis and every 12 hr thereafter.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4680808      PMCID: PMC444174          DOI: 10.1128/AAC.1.2.90

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Laboratory studies with a new cephalosporanic acid derivative.

Authors:  D R Chisholm; F Leitner; M Misiek; G E Wright; K E Price
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

2.  Renal damage associated with prolonged administration of ampicillin, cephaloridine, and cephalothin.

Authors:  E J Benner
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

3.  Evaluation of the Cutler-Orme method for administration of kanamycin during renal failure.

Authors:  R V McCloskey; G G Becker
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

4.  Cephalothin handling in patients undergoing hemodialysis.

Authors:  R C Venuto; M E Plaut
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

5.  Human pharmacokinetics of cephalexin.

Authors:  T Bergan; T Midtvedt; J Erikssen
Journal:  Pharmacology       Date:  1970       Impact factor: 2.547

6.  Paper chromatographic techniques for the determination of cephalothin and desacetylcephalothin in body fluids.

Authors:  M M Hoehn; H W Murphy; C T Pugh; N E Davis
Journal:  Appl Microbiol       Date:  1970-11

7.  Excretion of cephaloridine and cephalothin in patients with renal impairment.

Authors:  C M Kunin; N Atuk
Journal:  N Engl J Med       Date:  1966-03-24       Impact factor: 91.245

8.  Cephaloglycin and its biologically active metabolite desacetylcephaloglycin.

Authors:  W E Wick; W E Wright; H V Kuder
Journal:  Appl Microbiol       Date:  1971-03

9.  Laboratory and pharmacologic studies of BL-P-1322 (cephapirin sodium) in children.

Authors:  R C Gordon; F F Barrett; D J Clark; M D Yow
Journal:  Curr Ther Res Clin Exp       Date:  1971-06
  9 in total
  9 in total

1.  Hemodialysis-associated infections: treatment with cephapirin.

Authors:  S J Berman; W H Boughton; J G Sugihara; E G Wong; A W Siemsen
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

2.  Treatment of pneumonia and other serious bacterial infections with cephapirin.

Authors:  H G Robson; M I Bowmer
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

3.  Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.

Authors:  M Komiya; Y Kikuchi; A Tachibana; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 5.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 6.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

7.  Metabolic fate of SCE-129, a new antipseudomonal cephalosporin, after parenteral administration in rats and dogs.

Authors:  S Tanayama; K Yoshida; Y Kanai
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

8.  Pharmacokinetics of cefamandole in patients with renal failure.

Authors:  B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

9.  Metabolic fate of SCE-1365, a new broad-spectrum cephalosporin, after parenteral administration to rats and dogs.

Authors:  S Tanayama; K Yoshida; K Adachi; T Kondo
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.